Related Experiment Video
Updated: Dec 20, 2025
09:26
Identifying the Binding Proteins of Small Ligands with the Differential Radial Capillary Action of Ligand Assay DRaCALA
Published on: March 19, 2021
3.8K
Anticalins as alternative binding proteins for therapeutic use
1Lehrstuhl für Biologische Chemie, Technische Universität München, 85350 Freising-Weihenstephan, Germany. skerra@wzw.tum.de
Current Opinion in Molecular Therapeutics
|August 19, 2007
Summary
Researchers engineered novel binding proteins called anticalins from human lipocalins. These anticalins offer therapeutic applications as antagonists, targeting agents, and antidotes, with advantages over antibodies.
Area of Science:
- Protein engineering
- Immunology
- Biotechnology
Background:
- Human lipocalins possess a protein structure with hypervariable loops forming a ligand pocket.
- This structure is analogous to the complementarity-determining regions found in antibodies.
Purpose of the Study:
- To engineer novel binding proteins, termed anticalins, with high specificity and affinity.
- To explore the therapeutic potential of anticalins in various medical applications.
Main Methods:
- Targeted random mutagenesis and selection were employed to engineer anticalins.
- In vitro and in vivo studies were conducted to evaluate anticalin efficacy.
Main Results:
- Anticalins were successfully engineered for specific and tight binding to small molecules and protein antigens.
- Three therapeutic mechanisms were identified: antagonism, tissue targeting, and antidotes.
- Anticalins demonstrated advantages over antibodies, including smaller size and microbial production.
Conclusions:
- Anticalins represent a versatile platform for therapeutic development.
- Their unique properties offer practical advantages for drug delivery and toxin neutralization.
- Further research into anticalin applications in human therapy is warranted.
